MarkWide Research - Global Market Intelligence Platform
Report Details
Historical Year
2020-2024
Base Year
2025
Forecast Period
2026-2036
Published Date
May 2026
No. of Pages
155 Pages
Delivery Format
PDF + Excel
Home›Industries›Healthcare›Pharmaceuticals›Monkeypox Vaccine and Treatment Market

Monkeypox Vaccine and Treatment Market Size, Share, and Industry Trends Forecast 2026-2036

The Monkeypox Vaccine and Treatment Market valued at $865.4 Million in 2026 is projected to expand to $1,833.51 Million by 2035, advancing at a 8.70% CAGR over the analysis window. Public health organizations are scaling procurement of third-generation vaccines following WHO emergency use pathways. Bavarian Nordic's MVA-BN platform and SIGA Technologies' TPOXX antiviral anchor supply commitments across North America and Europe. Demand concentrates in the United States, where the Strategic National Stockpile maintains the world's largest smallpox-related countermeasure reserve.

Monkeypox Vaccine and Treatment Market Intelligence

Public health organizations is repositioning procurement priorities toward third-generation vaccines and novel antivirals after the 2022-2023 multi-country outbreak. Bavarian Nordic leverages its MVA-BN platform to dominate European and North American supply channels for replication-deficient vaccines. SIGA Technologies anchors the antiviral segment through TPOXX stockpiling contracts with national strategic reserves. Emergent BioSolutions sustains manufacturing scale across multiple biodefense product lines, while Chimerix competes in the antiviral niche with brincidofovir development.

Monkeypox vaccine and treatment encompasses prophylactic and therapeutic countermeasures targeting Orthopoxvirus infections, with third-generation vaccines employing modified vaccinia Ankara delivered via subcutaneous injection at dose volumes below 0.5 mL. The primary purpose centers on outbreak containment and strategic stockpile maintenance for both routine immunization and emergency response deployment. Live vaccines command the largest revenue share due to established regulatory pathways and proven efficacy profiles, while monoclonal antibodies represent the fastest-growing segment as developers pursue post-exposure prophylaxis indications. Antiviral drugs capture concentrated margin pools through government procurement contracts rather than commercial pharmacy channels.

FDA emergency use authorizations and EMA conditional marketing approvals shape product access timelines for novel vaccines and therapeutics, while WHO prequalification status determines procurement eligibility for low-income country buyers. The EU Green Deal and CSRD reporting requirements are forcing manufacturers to document supply chain emissions and cold-chain logistics footprints. Stakeholders must monitor regulatory divergence between FDA animal efficacy rule pathways and EMA human challenge trial demands for next-generation orthopoxvirus candidates.

Monkeypox Vaccine and Treatment Market Size and Forecast

Market Dynamics

Third-generation vaccine platforms are consolidating procurement power around replication-deficient candidates, compressing development timelines for orthopoxvirus countermeasures while national strategic reserves rewrite inventory specifications.

Growth Catalysts

  • WHO Emergency Use Pathway:The prequalification mechanism accelerates access for low-income country buyers, expanding addressable demand beyond traditional stockpile customers.
  • Subcutaneous delivery innovation:Dose-sparing intradermal administration protocols stretch finite supply during outbreak response, amplifying effective coverage per manufactured lot.
  • Biodefense procurement mandates:United States Strategic National Stockpile maintenance requirements sustain baseline demand regardless of epidemic cycles.

Market Restraints

  • Fill-finish capacity concentration:European contract manufacturing organizations control sterile injectable finishing for MVA-BN derived products, creating single-source vulnerability.
  • Animal efficacy rule dependency:FDA's requirement for well-characterized animal models when human challenge studies are unethical extends validation timelines for novel candidates.
  • Live vaccine cold chain:Ultra-low temperature distribution infrastructure gaps in tropical outbreak zones degrade product potency before administration.

Strategic Opportunities

  • Post-exposure prophylaxis indication:Monoclonal antibody developers pursuing shortened dosing windows after known exposure capture reimbursement premiums beyond pre-event vaccination.
  • EU Green Deal alignment:CSRD emissions disclosure requirements favor manufacturers documenting carbon-negative cold chain logistics, creating procurement preference.
  • Intradermal microarray patches:Solid-dose thermostable delivery formats eliminate refrigeration dependency for last-mile distribution in equatorial regions.

Industry Challenges

  • High-containment manufacturing workforce:Biosafety level 3 production facilities face persistent vacancies for trained operators and quality assurance specialists.
  • Cross-reactive serology assays:Distinguishing vaccine-induced immunity from natural orthopoxvirus exposure complicates efficacy endpoint measurement in clinical trials.

Report Scope

MarkWide Research
AttributesDetails
Report TitleMonkeypox Vaccine and Treatment Market
Market Size in 2026$865.4 Million
Market Size in 2035$1,833.51 Million
CAGR (2026 – 2036)8.7%
Historical Year2020-2024
Base Year2025
Forecast Period2026-2036
Segmentation
Product Type: Live Vaccines, Inactivated Vaccines, Antiviral Drugs, Monoclonal Antibodies
Therapy Area: Infectious Diseases, Viral Infections, Epidemic Response, Immunization
End User: Hospitals, Clinics, Research Institutions, Public Health Organizations
Delivery Mode: Intravenous, Subcutaneous, Intramuscular, Oral
Companies CoveredSIGA Technologies, Bavarian Nordic, Chimerix, Emergent BioSolutions, Gilead Sciences, Sanofi, Moderna, Johnson & Johnson, Tonix Pharmaceuticals, Others
Regions Covered
North America: US, Canada, Mexico
Europe: Germany, Italy, France, UK, Spain, Denmark, Sweden, Austria, Belgium, Finland, Turkey, Poland, Russia, Greece, Switzerland, Netherlands, Norway, Portugal, Rest of Europe
Asia Pacific: China, Japan, India, South Korea, Indonesia, Malaysia, Kazakhstan, Taiwan, Vietnam, Thailand, Philippines, Singapore, Australia, New Zealand, Rest of Asia Pacific
South America: Brazil, Argentina, Colombia, Chile, Peru, Rest of South America
Middle East & Africa: Saudi Arabia, UAE, Qatar, South Africa, Israel, Kuwait, Oman, North Africa, West Africa, Rest of MEA

Get the full picture before you read further.

Download a free sample with table of contents, companies, segments, and methodology.

Monkeypox Vaccine and Treatment Market Strategic Shifts & Innovations

Platform standardization around modified vaccinia Ankara derivatives is compressing competitive differentiation to manufacturing scale and regulatory access speed rather than fundamental immunological innovation.

Messenger RNA encoding orthopoxvirus antigens is rewriting the development economics for rapid-response vaccines, with synthetic manufacturing timelines collapsing from months to weeks. BARDA and CEPI funding recipients are advancing candidates through preclinical stages, positioning mRNA as the substrate for next-generation stockpile rotation. The structural consequence is a looming displacement of egg-based and cell-culture production for emergency-use indications.

EMA's conditional marketing authorization pathway for public health emergencies compresses review timelines for outbreak-countermeasure developers willing to accept post-authorization efficacy commitments. Manufacturers gain nine-to-twelve month accelerations versus standard centralized procedures, though pharmacovigilance obligations intensify. Small-cap developers lacking EU regulatory affairs infrastructure are partnering with established MVA-BN license holders to navigate rapporteur assignment.

National health security agencies are unbundling procurement from delivery, with CDC and ECDC establishing separate logistics contracts from product acquisition. This bifurcation favors specialized cold-chain operators over vertically integrated pharmaceutical companies. The United Kingdom's UKHSA pioneered this model during the 2022 outbreak, with NHS England now managing distribution independent of MHRA procurement decisions.

Monkeypox Vaccine and Treatment Market Segmentation

Monkeypox Vaccine and Treatment Market Segment

Orthopoxvirus countermeasures fragment across prophylactic and therapeutic modalities, with procurement patterns diverging between routine immunization programs and emergency stockpile deployment. Segmentation reveals how manufacturing scale, regulatory pathway, and cold-chain infrastructure shape competitive positioning across distinct product categories.

Product Type:

Live vaccines anchor standalone pre-exposure prophylaxis programs, while antiviral drugs and monoclonal antibodies embed within outbreak response protocols as reactive interventions.

  • Live Vaccines:Modified vaccinia Ankara derivatives deliver replication-deficient immunization via subcutaneous or intradermal routes. Demand concentrates in the United States Strategic National Stockpile and European national reserves, driven by biodefense procurement mandates that sustain baseline orders independent of epidemic cycles.
  • Antiviral Drugs:Small-molecule therapeutics targeting viral DNA replication provide post-exposure treatment for confirmed infections. Procurement flows through government stockpiling contracts rather than commercial pharmacy channels, with SIGA Technologies' TPOXX dominating supply commitments across North America and Europe.
  • Inactivated Vaccines:Non-replicating candidates offer alternatives for immunocompromised populations excluded from live-virus products.
  • Monoclonal Antibodies:Engineered immunoglobulins pursue post-exposure prophylaxis indications with shortened dosing windows after known exposure.

Volume placements concentrate in Live Vaccines; the faster expansion belongs to Monoclonal Antibodies.

Therapy Area:

Cost tiering separates mass vaccination campaigns from targeted epidemic containment, with infectious disease programs absorbing the largest procurement budgets.

  • Infectious Diseases:Broad-spectrum orthopoxvirus countermeasures address both routine immunization and emergency deployment scenarios. Procurement scales through WHO prequalification pathways that accelerate access for low-income country buyers beyond traditional stockpile customers.
  • Epidemic Response:Rapid-deployment stockpiles require thermostable formulations and dose-sparing administration protocols. Demand clusters in tropical outbreak zones where ultra-low temperature distribution infrastructure gaps degrade product potency before administration.
  • Viral Infections:Narrower indications target specific orthopoxvirus species with differentiated clinical presentations.
  • Immunization:Preventive programs integrate with existing smallpox eradication legacy infrastructure.

Procurement budgets concentrate in Infectious Diseases; the steepest expansion trajectory appears in Epidemic Response.

End User:

Customer type determines order scale and reimbursement pathway, with public health organizations commanding multi-year supply contracts unavailable to institutional buyers.

  • Public Health Organizations:National health security agencies and international bodies coordinate multi-million dose procurements through centralized tender processes. The CDC and ECDC unbundle acquisition from delivery, establishing separate logistics contracts that favor specialized cold-chain operators.
  • Hospitals:Acute care facilities manage outbreak containment within defined catchment areas, requiring rapid replenishment capabilities. Demand concentrates in metropolitan clusters with international travel connectivity that elevates importation risk.
  • Clinics:Outpatient settings administer pre-exposure prophylaxis to occupational risk groups including laboratory personnel.
  • Research Institutions:Academic and government laboratories conduct efficacy studies and variant surveillance.

Contract value concentrates in Public Health Organizations; the fastest volume growth emerges in Hospitals.

Delivery Mode:

Supply concentration in sterile injectable manufacturing shapes route availability, with subcutaneous administration dominating current dose-sparing protocols.

  • Subcutaneous:Dose-sparing intradermal administration protocols stretch finite supply during outbreak response, amplifying effective coverage per manufactured lot. European contract manufacturing organizations control fill-finish capacity for MVA-BN derived products.
  • Intravenous:Antiviral drugs requiring hospital infusion target severe disease presentations with therapeutic monitoring. Administration concentrates in tertiary care centers with biocontainment capabilities.
  • Intramuscular:Conventional injection routes persist for legacy vaccine formulations.
  • Oral:Solid-dose formats eliminate refrigeration dependency for last-mile distribution in equatorial regions.

Manufacturing scale concentrates in Subcutaneous; the most rapid technology transition targets Oral.

Monkeypox Vaccine and Treatment Market Segmentation

Need this report tailored to your region?

Request specific countries, segments, or companies — tailored to your requirements.

Regional Outlook

Bioscience parks in Maryland and Massachusetts concentrate biodefense manufacturing capacity, attracting federal procurement contracts and specialized cold-chain logistics operators to the I-270 corridor.

United States

The Strategic National Stockpile sustains baseline demand through multi-year supply contracts with Bavarian Nordic and SIGA Technologies. FDA's animal efficacy rule shapes validation timelines for novel orthopoxvirus candidates. Maryland's I-270 biotechnology corridor hosts fill-finish facilities for MVA-BN derived products.

Germany

EMA conditional marketing authorizations accelerate review timelines for outbreak countermeasures. The EU Green Deal and CSRD reporting requirements force manufacturers to document cold-chain emissions. Bavaria's vaccine manufacturing cluster anchors European production of replication-deficient vaccines.

United Kingdom

UKHSA pioneered unbundled procurement models separating product acquisition from NHS England distribution. MHRA emergency use pathways enabled rapid deployment during the 2022 outbreak. London's national health security infrastructure coordinates multi-million dose tenders.

Denmark

Bavarian Nordic's headquarters anchors Nordic biodefense supply chains to North American and European reserves. The Danish Medicines Agency aligns with EMA centralized procedures for orthopoxvirus countermeasures. Copenhagen's pharmaceutical cluster specializes in high-containment viral vector manufacturing.

Canada

Health Canada leverages FDA emergency use authorizations through reliance pathways for rapid product access. The Public Health Agency of Canada maintains strategic reserves through Public Services and Procurement Canada. Ontario's Toronto-Waterloo bioscience corridor hosts contract manufacturing for sterile injectables.

Monkeypox Vaccine and Treatment Market Key Industry Players

Top-tier vendors anchor government stockpile contracts, while mid-cap developers pursue novel platform technologies through BARDA and CEPI funding mechanisms. The market structure consolidates around replication-deficient vaccine platforms and small-molecule antivirals. Two strategic archetypes dominate: vertically integrated biodefense contractors with established regulatory access, and platform-technology developers seeking emergency use pathways. Competitive moves center on manufacturing scale expansion and strategic licensing of MVA-BN derivatives.

Among established biodefense contractors, Bavarian Nordic and SIGA Technologies occupy positions as archetypal stockpile suppliers, with Emergent BioSolutions representing the diversified manufacturing tier. These entities exemplify contrasting strategic postures: the MVA-BN platform licensor versus the antiviral specialist, both sustained by government procurement rather than commercial pharmacy channels. Moderna and Chimerix sit within the development-stage tier, pursuing mRNA and novel antiviral platforms respectively.

Leading Market Players
SIGA Technologies
Bavarian Nordic
Chimerix
Emergent BioSolutions
Gilead Sciences
Sanofi
Moderna
Johnson & Johnson
Tonix Pharmaceuticals
Others
Please note: The company list above is for reference and is subject to change. The final study will cover 15–20 leading companies in this market, and the final selection can be tailored to the client's specific requirements.

Cost & Logistics Intelligence

US Strategic National Stockpile multi-year procurement mandates compress supplier margins while demanding guaranteed surge capacity, forcing manufacturers to embed cold-chain redundancy costs into contract pricing and prioritize fill-finish scale over R&D investment.

Pricing Analysis

Short lead-time premiums dominate government procurement contracts, with emergency outbreak response orders commanding price multiples over scheduled stockpile replenishment. Three-tier pricing structure across emergency surge, scheduled rotation, and pre-positioned inventory levels separates biodefense readiness tiers. Cost compression in scheduled procurement is intensifying because BARDA and CEPI funding recipients are advancing mRNA alternatives that threaten MVA-BN platform incumbency. Public health organizations exhibit lowest price sensitivity due to statutory stockpile maintenance requirements, while research institutions face strict budget caps that amplify competitive bidding pressure.

Supply Chain Analysis

Direct-to-government channels handle strategic reserve procurement, bypassing wholesale distributors entirely. Fill-finish capacity concentrates in Denmark, Germany, and the United States, with Bavarian Nordic's Copenhagen facility anchoring European MVA-BN output. High-containment viral vector manufacturing draws from specialized BSL-3 infrastructure, fetal bovine serum, and single-use bioreactor consumables. Single-source vulnerability pervades sterile injectable finishing, where European contract manufacturing organizations control critical-path capacity for replication-deficient vaccines. Distribution runs through federally contracted cold-chain operators with validated ultra-low temperature custody documentation.

Monkeypox Vaccine and Treatment Market SWOT Analysis

Get the full picture before you read further.

Download a free sample with table of contents, companies, segments, and methodology.

Analyst Recommendations

This market is a vertical-integration race. Manufacturers are pursuing upstream control over high-containment production infrastructure to secure regulatory priority and lock out platform competitors.

For Market Incumbents: Deploy MVA-BN platform licensing as a defensive perimeter against mRNA displacement threats. Secure exclusive fill-finish partnerships with European contract manufacturing organizations to constrain competitor capacity access. Accelerate post-exposure prophylaxis indication expansion for monoclonal antibodies to capture reimbursement premiums beyond pre-event vaccination tiers. For New Entrants and Emerging Players: Enter via thermostable solid-dose delivery formats that eliminate cold-chain dependency in tropical outbreak zones. Target epidemic response procurement channels where ultra-low temperature infrastructure gaps degrade incumbent product potency. Pursue WHO prequalification status as the primary go-to-market angle to unlock low-income country demand beyond traditional stockpile customers. For Investors and Strategic Acquirers: The window for entry favors platform-technology developers with emergency use pathway experience and BARDA funding relationships. Long-term viability hinges on regulatory access speed rather than manufacturing scale alone. Watch for EMA conditional marketing authorization accelerations as the inflection signal indicating which candidates will capture nine-to-twelve month review advantages.
Strategic Initiative Industry Significance
Manufacturing Scale-Up High-containment BSL-3 capacity expansion in Denmark and Maryland secures MVA-BN supply commitments.
Regulatory Approval Pathway FDA animal efficacy rule navigation accelerates novel orthopoxvirus candidate validation timelines.
Licensing Agreement MVA-BN derivative sublicensing to mid-cap developers spreads platform risk across multiple indications.
Clinical Trial Advancement Post-exposure prophylaxis dosing window compression trials unlock monoclonal antibody reimbursement premiums.
Pipeline Diversification mRNA orthopoxvirus antigen programs position developers for next-generation stockpile rotation displacement.

Research Approach

FDA filings, EMA centralized procedure documentation, and WHO prequalification status records formed the secondary backbone, cross-referenced against ClinicalTrials.gov entries and national stockpile procurement disclosures. Primary interviews with biodefense procurement officers, regulatory affairs leads at vaccine developers, high-containment facility operations directors, and GPO contracts managers validated demand assumptions and manufacturing capacity constraints. Bottom-up and top-down triangulation reconciled dose-volume forecasts with government budget appropriation trajectories.

Bottom-up modeling anchored volume projections to disclosed Strategic National Stockpile maintenance requirements and ECDC unbundled procurement patterns, while top-down validation assessed macro-level biodefense spending envelopes. Segmentation across product type, therapy area, end user, and delivery mode informed granular demand disaggregation. CAGRs were derived from multi-year contract value analysis and dose-schedule evolution assumptions. Forecast inputs included cold-chain logistics cost trajectories and BSL-3 workforce availability indices.

Forecast precision tightens around the base case; tail outcomes carry wider variance under outbreak-driven emergency procurement surges or regulatory pathway delays for novel platforms. Periodic stress-testing of base assumptions is recommended, particularly regarding mRNA platform displacement timelines and EU Green Deal emissions disclosure enforcement intensity.

Need Custom Data?

Can't find what you're looking for? Our analysts can build a custom report tailored to your exact requirements.

1,000+

Global Clients

150+

Countries Covered

65,000+

Reports Available

Frequently Asked Questions

Why Work With MWR

Trusted by 1,000+ businesses across 150+ countries for high-stakes market decisions.

Ready to access intelligence that moves business?

Browse Reports →

Trusted by Global Leaders

From Fortune-level organizations to global SMEs, we provide intelligence for high-stakes decisions.

Multi-Language Support

Research available in French, German, Spanish, Chinese, and more.

ISO & IAF Certified

Globally aligned quality standards ensuring methodological discipline and data integrity.

Competitive Relevance

Free inclusion of 3–4 additional companies of your choice in every report.

Customized Insights

Tailored intelligence for market entry, niche expansion, or competitive benchmarking.

Post-Sale Assistance

Dedicated coordination to help interpret findings and address queries post-delivery.

Cutting-Edge Methods

Structured data collection, advanced analytics, and expert validation for reliable forecasts.

Value for Investment

Credible, structured intelligence at a cost that makes strategic sense.

What Our Clients Say

"

My team needed the real numbers on AI spending for our Reinvention Services work. MarkWide delivered. No fluff, just a clear look at where the money is actually going. It saved us about three weeks of guesswork.

Accenture

"

We recently leaned on MarkWide Research for a deep dive into the evolving snacking habits within Southeast Asia. Their report on the premium biscuit segment was exceptionally detailed, providing us with the specific consumer sentiment data we needed to refine our regional flavor strategy. It wasn't just a data dump; the cultural nuances they captured helped us avoid several localization pitfalls.

Mondelez

Director of Global Consumer Insights

"

For a recent engagement in the automotive sector, we needed rigorous, independent verification of EV battery recycling capacities. MWR delivered a report that made our work easier. Their ability to segment the competitive landscape by chemical composition and regional throughput was exactly the kind of 'hard-to-find' intel that our team was looking for.

BCG

"

We were looking for a report on Xcelerator ecosystem's potential and got in touch with MarkWide's team through one of my old colleagues who worked with them in the past. Their research team was incredibly polite and were always available for us which was important for my team as this was a custom project. Their methodology for tracking industrial IoT adoption gave our R&D heads the clarity needed to prioritize our next-gen sensor development.

Siemens

Head of Industrial Digitalization

"

During a recent M&A project, we needed a fast, reliable breakdown of the Fintech landscape in Southeast Asia. MarkWide came through with a report that was actually readable and focused on the metrics that matter. It saved my team a good week of primary research, which, given our timelines, was a massive win.

KPMG

Advisory Partner

"

We tapped MarkWide Research for a deep dive into the ESG reporting software market. At Deloitte, our clients expect us to have the most current insights, and this report didn't disappoint. It provided a breakdown of the competitive field that was far more detailed than what we were expecting.

Deloitte

Lead Consultant, Sustainability Services

"

For our semiconductor division at Samsung, the supply chain forecast from MarkWide was incredibly useful. It provided a realistic outlook on raw material availability that helped us refine our production timelines. No fluff, just the data we needed to make a tough call.

Samsung

"

The value for our organization comes from three things: depth of research, specificity of segments and being easy to work with. As important as the first two are, the third can't be underestimated. MarkWide Research, maybe more than any other research vendor, wants to know what is top of mind for our team and what big questions we are grappling to answer. Their customer first approach and high value engagement model have given us great analysis and excellent value for money.

3M

"

I can share that it was a positive experience wherein MarkWide Research demonstrated flexibility to adapt to our needs and delivered an excellent report that fits all our requirements. Personally, I liked the timely follow up by the team and we will definitively reach out in case more research support is required.

VITO

Buy Now